Back to Search
Start Over
122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515).
- Source :
-
Annals of Oncology . 2022 Supplement 2, Vol. 33, pS88-S88. 1p. - Publication Year :
- 2022
- Subjects :
- *NON-small-cell lung carcinoma
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 155963235
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.02.149